Leuprolide (brand name Lupron) is a synthetic GnRH analog — a hormone mimic that first stimulates, then shuts down the body's sex hormone production — used clinically to treat endometriosis, uterine fibroids, and certain hormone-sensitive cancers.
What it does
Leuprolide works by mimicking gonadotropin-releasing hormone (GnRH), the signal the hypothalamus sends to the pituitary gland to trigger release of LH and FSH — the hormones that tell the ovaries and testes to make estrogen and testosterone. When GnRH arrives in short natural pulses, it drives hormone production. When it arrives continuously, as leuprolide does, it overwhelms the pituitary's receptors and causes them to downregulate (reduce in number and responsiveness). After an initial brief surge, LH and FSH output drops sharply PubMed 1795229.
With LH and FSH suppressed, the gonads stop producing sex steroids. Estrogen in women and testosterone in men fall to near-castrate levels within a few weeks of starting treatment. Tissues that depend on those hormones — endometrial lesions, fibroid tissue, prostate tumors — lose their growth signal and become quiescent. The effect is reversible once the drug is stopped PubMed 16182402. Leuprolide is not active when taken orally; it must be injected or delivered via implant PubMed 36557850.
What the evidence shows
Endometriosis Strong clinical evidence from multiple randomized controlled trials; FDA-approved indication
Leuprolide at 3.75 mg monthly is an FDA-approved treatment for endometriosis — a condition where uterine-lining tissue grows outside the uterus, causing chronic pain. Clinical trials have demonstrated meaningful reductions in pelvic pain and visible endometriotic lesions compared to placebo. When combined with norethindrone acetate (add-back therapy) to partially offset estrogen loss, it can be used for initial symptom management and for managing symptom recurrence. Total treatment duration with add-back therapy is capped at 12 months due to measurable losses in bone mineral density with prolonged use.
Uterine fibroids (leiomyomata) Strong clinical evidence; FDA-approved, limited to short-term preoperative use
For women with anemia caused by uterine fibroids who are heading toward surgery, leuprolide is approved as a short-term adjunct to iron therapy to improve blood counts before the procedure. By suppressing estrogen, it reduces fibroid size and associated bleeding. Use is limited to approximately three months and is not a standalone long-term treatment for fibroids.
Ovarian protection during chemotherapy Moderate clinical evidence; active research ongoing
Suppressing ovarian function with leuprolide during chemotherapy has been investigated as a strategy to preserve fertility in women with conditions like rheumatic disease receiving cyclophosphamide NCT01257802. The rationale is that a quiescent ovary may be less vulnerable to chemotherapy-induced damage. Evidence is encouraging but not yet definitive across all patient populations.
Skeletal and hormonal effects in youth Emerging evidence; ongoing research
Research is actively examining how GnRH analog-induced hormone suppression affects bone mineral density and marrow composition in younger populations NCT04203381. This is particularly relevant in the context of puberty suppression, where the long-term skeletal consequences remain an area of active study and genuine clinical uncertainty.
How it's used
In clinical settings, leuprolide is administered by intramuscular or subcutaneous injection — not orally, as it is inactive by that route PubMed 36557850. The standard depot formulation for endometriosis and fibroids is 3.75 mg injected once monthly; a 3-month depot formulation of 11.25 mg also exists. Dose and interval vary by indication — prostate cancer protocols differ from gynecological ones. In studies and self-reported protocols, monthly dosing is standard for hormonal suppression in women, with the 3-month depot used for convenience. Add-back therapy (low-dose estrogen/progestogen) is typically co-administered when treatment extends beyond a few months to limit bone loss. Consult prescribing information or a licensed clinician for indication-specific dosing.
Side effects and safety
The dominant side effect profile mirrors surgical menopause or androgen deprivation: hot flashes, reduced libido, vaginal dryness in women, and in men, erectile dysfunction and fatigue. Injection site reactions, headache, and nausea are commonly reported PubMed 1795229. Depression and mood changes are a moderate concern noted in clinical use. The most clinically significant risk with prolonged use is bone mineral density loss — measurable within months of starting and the primary reason treatment duration is capped at 12 months for endometriosis NCT04203381. Leuprolide is absolutely contraindicated in pregnancy (it can harm a developing fetus) and in undiagnosed abnormal uterine bleeding. Relative contraindications include pre-existing cardiovascular disease, history of thromboembolism (especially when norethindrone is added), and osteoporosis. The initial hormone surge ('flare') that occurs in the first one to two weeks of treatment can temporarily worsen hormone-sensitive conditions — a clinically important consideration in prostate cancer patients. Long-term safety data beyond approved indications and durations remains limited.
Bottom line
Leuprolide has robust, decades-long clinical evidence supporting its use in endometriosis, uterine fibroids, and hormone-sensitive cancers — it's a well-characterized drug, not an experimental compound. Its side effect burden, particularly bone loss and menopausal symptoms, is real and dose-duration dependent, which is why it's used under close medical supervision with defined treatment caps. It is not appropriate for self-administration outside of a structured clinical relationship.